Abstract: Chinese Clinical Trials Registry ChiCTR2200060974. Registered on June 14, 2022. The status of the trial is recruiting, and the estimated study completion date is December 31, 2024.
Introduction
For approximately 30% of patients with focal epilepsy, pharmacological treatments fail to provide adequate seizure control, leading to a diagnosis of drug-resistant epilepsy (DRE). While traditional resective surgery—the surgical removal of the epileptogenic focus—is considered the "gold standard," its high level of invasiveness carries significant risks of collateral neurological damage, including memory loss, visual field defects, and hemiplegia.
This paper presents a protocol for a multicenter randomized controlled trial (RCT) designed to evaluate whether minimally invasive, robot-assisted stereotactic lesioning can match the effectiveness of traditional surgery while significantly improving safety profiles. Specifically, the study focuses on Radiofrequency Thermocoagulation (RF-TC) and Laser Interstitial Thermal Therapy (LITT).
Study Design and Methodology
The trial is a prospective, three-arm RCT involving 240 participants across three major neurological centers in China. The study is powered to test for "non-inferiority," meaning the goal is to demonstrate that minimally invasive techniques are not significantly less effective than resection at stopping seizures, while being substantially safer.
Randomization and Intervention
Participants are assigned to one of three treatment arms using a two-stage randomization process. Patients are first assigned 1:1 to either "lesioning" or "resection." Those in the lesioning group are further randomized 4:1 between RF-TC and LITT, resulting in an overall ratio of 5:4:1 (Resection:RF-TC:LITT).
- Resective Surgery: Traditional open surgery (e.g., lobectomy).
- SEEG-guided RF-TC: Utilizing electrodes to deliver radiofrequency energy to destroy target tissue.
- MRI-guided LITT: Utilizing a laser probe with real-time MRI thermal monitoring for precise ablation.
To ensure high-precision placement and reduce human error, the trial utilizes the Sinovation SR1 stereotactic robot for all electrode and laser probe insertions.
Outcomes and Data Collection
The primary outcome is the seizure remission rate at 12 months post-operation. Secondary outcomes include:
- Neurological Impairment: Measured via the NIHSS scale.
- Quality of Life: Assessed through QOLIE-89/48 surveys.
- Cognitive Function: Evaluated using Wechsler Intelligence Scales.
- Economic Impact: Analysis of total medical costs.
The "Less is More" Hypothesis
The central hypothesis of this study is that the trade-off between radical resection and targeted lesioning favors the latter. While resection may offer a slightly higher probability of total seizure freedom, the researchers expect postoperative neurological impairment rates to be approximately 2% for the lesioning groups, compared to 11% for the resection group. This "nerve function protection" is a critical factor for patient quality of life.
Limitations and Future Work
The study acknowledges certain limitations, including a 4:1 randomization ratio between RF-TC and LITT which may limit direct statistical comparisons between the two minimally invasive methods. Additionally, while the 12-month follow-up is standard, longer-term data (2-5 years) may be required in the future to assess late-stage seizure recurrence.
Recruitment for the trial began in September 2022, and the results are expected to provide definitive high-level evidence to guide the surgical management of focal drug-resistant epilepsy.
Summary updated